The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the results of a Phase II, open-label study (NCT03538041) investigating parsaclisib for the treatment of primary autoimmune hemolytic anemia. The agent resulted in a consistent elevation in hemoglobin, allowing patients to become transfusion-independent and independent of steroid treatment. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Autoimmune hemolytic anemia, warm and cold, of course, is not always a deadly disease, but we have a lot of patients who need to go through two or three or four rounds of treatment and it becomes a chronic disease. That’s why we’re always looking for novel treatments. And one of the ideas was to target the B-cells that are involved with an PI3 kinase inhibitor, in this case, parsaclisib...
Autoimmune hemolytic anemia, warm and cold, of course, is not always a deadly disease, but we have a lot of patients who need to go through two or three or four rounds of treatment and it becomes a chronic disease. That’s why we’re always looking for novel treatments. And one of the ideas was to target the B-cells that are involved with an PI3 kinase inhibitor, in this case, parsaclisib.
And what we saw was particularly striking in the warm hemolytic anemias, but also in the cold. We saw a consistent elevation in hemoglobin. So, patients became transfusion-independent and also independent of steroid treatments.
I think this treatment is fantastic. It has some of the problems that PI3 kinase inhibitors always have, which is mainly autoimmune side effects in terms of pneumonitis or colitis and things like that. But I think it’s a really good option for patients who went through the first or second round of treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
